5:25 PM
 | 
Sep 12, 2013
 |  BC Extra  |  Company News

NHS covering Alexion's Soliris until NICE decision

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) said NHS England will cover Soliris eculizumab to treat atypical hemolytic uremic syndrome (aHUS) pending a decision from NICE, which is expected...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >